title: [Use of antiplatelet agents in patients with chronic kidney disease: what is the evidence?].
abstract: Patients with chronic kidney disease are particularly prone to cardiovascular disorders because of a tendency to thrombosis, but also have an enhanced hemorrhagic risk. The use of antiplatelet agents in this subset of patients is not yet well defined and caution should be given on which AAP is prescribed to them.
authors.forename: Aline
authors.initials: A
authors.lastname: Gabrielli
authors.forename: Yassine
authors.initials: Y
authors.lastname: Bouatou
authors.forename: Patrick
authors.initials: P
authors.lastname: Saudan
mesh_terms: D000241:Adenosine / Q000031:analogs & derivatives / Q000627:therapeutic use; D001791:Blood Platelet Disorders / Q000209:etiology / Q000517:prevention & control; D000077144:Clopidogrel; D055317:Evidence-Based Practice; D006801:Humans; D010879:Piperazines / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D000068799:Prasugrel Hydrochloride; D051436:Renal Insufficiency, Chronic / Q000150:complications / Q000188:drug therapy*; D013876:Thiophenes / Q000627:therapeutic use; D013927:Thrombosis / Q000209:etiology / Q000517:prevention & control; D000077486:Ticagrelor; D013988:Ticlopidine / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D010879:Piperazines; D010975:Platelet Aggregation Inhibitors; D013876:Thiophenes; D000077144:Clopidogrel; D000068799:Prasugrel Hydrochloride; D000077486:Ticagrelor; D000241:Adenosine; D013988:Ticlopidine